Odyssey Therapeutics to Present at September Investor Conferences as It Advances Autoimmune Pipeline
核心洞察
Odyssey Therapeutics (搜索), a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases (搜索), announced management participation in three investor conferences in September 2026.
The company will hold fireside chats at the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and H.C. Wainwright Global Investment Conference.
Odyssey, founded in 2021, has built an internally discovered portfolio with its first program advancing through multiple clinical milestones toward deep and durable remission in inflammatory diseases.
Odyssey Therapeutics (搜索), Inc. (Nasdaq: ODTX), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases (搜索), announced that members of its management team will participate in three upcoming investor conferences in September 2026.
The company will hold a fireside chat at the 2026 Cantor Global Healthcare Conference on September 9 at 8:35 AM ET in New York, NY. Odyssey will also participate in the Morgan Stanley 24th Annual Global Healthcare Conference with a fireside chat on September 14 at 10:45 AM ET, and in the H.C. Wainwright 28th Annual Global Investment Conference with a fireside chat on September 15 at 1:00 PM ET, both also in New York, NY.
Where available, live webcasts will be accessible under the "News and Events" section in the Investors area of the company's website at www.odysseytx.com. Replays of the webcasts will be made available on the Events page of Odyssey's investor website and archived for 60 days.
Company Focus and Pipeline
Odyssey Therapeutics (搜索) develops medicines designed to precisely target disease pathology in autoimmune and inflammatory diseases (搜索). Since its founding in 2021, the company has built a portfolio of internally discovered and developed medicines, with its first program advancing through multiple clinical milestones.
The company's portfolio leverages the scientific expertise of its team of experienced drug hunters and a comprehensive suite of tools to efficiently advance product candidates that Odyssey believes have the potential to induce deep and durable remission for patients across several inflammatory diseases with unmet need.